But then again Rockwell's Iron delivery is better in ESA savings and done while the patient is recieving the Dialsate and not another procedure.Accumulation before the run-up which has started before the trial has ended in the latter part of May.
They need a partnership/lic. deal domestically and int'l. This would shore up the bal. sheet. Mgmt has been talking about this for months and months and..............Hopefully before April 30th. The PRIME Study results from Feb. 4th provide ample evidence for a successful SFP outcome. The CEO is a sales guy, he should be able to make this pitch.
It will come as he was side tracked during the price raid on the shares by some deceitful short traders making him take a low ball hasty decision to stop the bloodbath by them.They have much more than Kerx with the revenues being $48-50 Million and another drug soon to be approved by the FDA for replenishing the D vitamin which will also increase revenue substancially for the company.They also don't have 70 Million shares out and only 26 Million as on their reports.Gold is falling and many will be back in the pharmaceuticials as this is a Prime target coming up on the PH3 completion of the Cruise trial.The market is the same as Kerx being $650 Million.